This article is for informational and marketing purposes only and does not constitute medical advice
BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of a gastric protective protein, studied in preclinical models for its role in cytoprotection, angiogenesis, and connective-tissue repair
The question that researchers, clinicians, and patients are increasingly asking is not whether BPC-157 does something, but what the right BPC-157 dosage and protocol looks like for a given purpose
Cagrilintide is not a controlled drug under the Misuse of Drugs Act 1971, and it can be supplied lawfully in the UK as a research chemical
This makes the IV therapy more effective
Supports detoxification, immunity, antioxidant protection, and overall vitality